Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Carman K. M. Ip (), Patrick K. S. Ng, Kang Jin Jeong, S. H. Shao, Zhenlin Ju, P. G. Leonard, Xu Hua, Christopher P. Vellano, Richard Woessner, Nidhi Sahni, Kenneth L. Scott and Gordon B. Mills
Additional contact information
Carman K. M. Ip: The University of Texas MD Anderson Cancer Center
Patrick K. S. Ng: The University of Texas MD Anderson Cancer Center
Kang Jin Jeong: The University of Texas MD Anderson Cancer Center
S. H. Shao: The University of Texas MD Anderson Cancer Center
Zhenlin Ju: The University of Texas MD Anderson Cancer Center
P. G. Leonard: The University of Texas MD Anderson Cancer Center
Xu Hua: The University of Texas MD Anderson Cancer Center
Christopher P. Vellano: The University of Texas MD Anderson Cancer Center
Richard Woessner: AstraZeneca Phamaceuticals
Nidhi Sahni: The University of Texas MD Anderson Cancer Center
Kenneth L. Scott: Baylor College of Medicine
Gordon B. Mills: The University of Texas MD Anderson Cancer Center

Nature Communications, 2018, vol. 9, issue 1, 1-14

Abstract: Abstract Activation of platelet-derived growth factor receptor alpha (PDGFRA) by genomic aberrations contributes to tumor progression in several tumor types. In this study, we characterize 16 novel PDGFRA mutations identified from different tumor types and identify three previously uncharacterized activating mutations that promote cell survival and proliferation. PDGFRA Y288C, an extracellular domain mutation, is primarily high mannose glycosylated consistent with trapping in the endoplasmic reticulum (ER). Strikingly, PDGFRA Y288C is constitutively dimerized and phosphorylated in the absence of ligand suggesting that trapping in the ER or aberrant glycosylation is sufficient for receptor activation. Importantly, PDGFRA Y288C induces constitutive phosphorylation of Akt, ERK1/2, and STAT3. PDGFRA Y288C is resistant to PDGFR inhibitors but sensitive to PI3K/mTOR and MEK inhibitors consistent with pathway activation results. Our findings further highlight the importance of characterizing functional consequences of individual mutations for precision medicine.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-06949-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06949-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-06949-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().